The challenge of measuring IL-33 in serum using commercial ELISA: lessons from asthma

M. E. Ketelaar1,2,3, M. C. Nawijn2, D. E. Shaw1, G. H. Koppelman3,a and I. Sayers1,a

1Division of Respiratory Medicine, University of Nottingham, Nottingham, UK, 2University Medical Center Groningen, Department of Pathology and Medical Biology, Laboratory of Allergology and Pulmonary Diseases, University of Groningen, Groningen, The Netherlands and 3University Medical Center Groningen, Pediatric Pulmonology and Pediatric Allergology, Beatrix Children’s Hospital, Groningen Research Institute for Asthma and COPD, University of Groningen, Groningen, The Netherlands

Summary

Background Interleukin-33 (IL-33) has been subject of extensive study in the context of inflammatory disorders, particularly in asthma. Many human biological samples, including serum, have been used to determine the protein levels of IL-33, aiming to investigate its involvement in asthma. Reliable methods are required to study the association of IL-33 with disease, especially considering the complex nature of serum samples.

Objective We evaluated four IL-33 ELISA kits, aiming to determine a robust and reproducible approach to quantifying IL-33 in human serum from asthma patients.

Methods IL-33 levels were investigated in serum of well-defined asthma patients by the Quantikine, DuoSet (both R&D systems), ADI-900-201 (Enzo Life Sciences), and SKR038 (GenWay Biotech Inc San Diego USA) immunoassays, as well as spiking experiments were performed using recombinant IL-33 and its soluble receptor IL-1RL1-a.

Results We show that 1) IL-33 is difficult to detect by ELISA in human serum, due to lack of sensitivity and specificity of currently available assays; 2) human serum interferes with IL-33 quantification, in part through IL-1RL1-a; and 3) using non-serum certified kits may lead to spurious findings.

Conclusion and Clinical Relevance If IL-33 is to be studied in the serum of asthma patients and other diseases, a more sensitive and specific assay method is required, which will be vital for further understanding and targeting of the IL-33/IL-1RL1 axis in human disease.

Keywords asthma, IL-1RL1, IL-33, immunoassay, interference, sensitivity, serum, specificity

Submitted 28 September 2015; revised 26 January 2016; accepted 1 February 2016
of (extracellular) IL-33 is its capture by the soluble form of its receptor (IL-1RL1-a or sST2), thereby preventing the immunogenic activity of extracellular IL-33 [1, 4]. In asthma, the IL-33/IL-1RL1 pathway seems to be dysregulated. Indeed, IL-33 levels have been reported to increase in induced sputum, bronchial lavage fluid (BALF), and lung epithelial cells of patients with asthma compared to non-asthmatic controls [5, 6]. Despite these studies, it is unknown whether serum levels of IL-33 represent a suitable biomarker for asthma or subgroups of asthma.

In this study, we set out to investigate the level of IL-33 in serum of well-characterized patients with asthma, aiming to evaluate its suitability as a biomarker for asthma phenotypes. As this requires a robust method to quantify IL-33 in human serum, we evaluated four human IL-33 ELISA kits including three assays specifically designed for serum samples (Quantikine® by R&D systems Abingdon UK, ADI-900-201® by Enzo LifeScience Exeter UK, SKR03® by GenWay Biotech San Diego USA). We also included an assay for quantification of IL-33 in general biological samples (DuoSet® by R&D systems Abingdon UK). For IL-33 quantification, we obtained serum samples from 45 asthma patients recruited from both Groningen and Nottingham (mild asthma n = 25, moderate asthma n = 10, severe asthma n = 10, based on the GINA 2012 criteria, http://www.ginasthma.org/), of whom n = 17 (mild asthma n = 7, moderate asthma n = 5, severe asthma n = 5) were used across all four methods. Serum was separated from whole blood samples in serum separating tubes using centrifugation after a 20–40 min clotting time at room temperature. Serum was aliquoted and immediately frozen at −80°C. Transportation from the hospitals to the research facility was carried out on dry ice. Stocks were kept at −80°C, while working tubes were stored at −20°C. Care was taken to keep identical freeze/thaw cycles among the comparisons.

Both studies had approval of local medical ethical committees, and patients had given written informed consent. Recombinant IL-33 (from each of the kits) and IL-1RL1-a (sST2; from R&D) were used to determine specificity, sensitivity, and interference of IL-1RL1 in each of the assays.

Using the three kits specifically designed for serum, the level of IL-33 was at or below the lower limit of detection (LLD) in serum from asthma patients (Table 1 and Fig. 1, LLD being the detection limit as defined by each manufacturer). In contrast, the DuoSet showed a clear signal above the LLD in 76% of the samples, and a higher signal in ~17.5% of the serum samples. Indeed, when directly compared to the other assays, the DuoSet assay showed multiple deviating values, some of which were in a tenfold higher range (Fig. 1b). This discrepancy is striking and could not easily be explained by possible confounding factors, such as asthma severity.

Table 1. Percentage of positive signals for each IL-33 immunoassay. Shown are the discrepancies between the relative number of positive signals for the Quantikine, GenWay, EnzoLS, and DuoSet IL-33 immunoassays, by comparing the percentage of signals above background and above the lower limit of detection of each assay.

| IL-33 assay | N | % of samples above background | % of samples above LLD |
|-------------|---|-------------------------------|------------------------|
| Quantikine  | 45 | 38                            | 2                      |
| GenWay      | 22 | 23                            | 0                      |
| Enzo LS     | 17 | 8                             | 0                      |
| DuoSet      | 17 | 100                           | 76                     |

**Table 1.** Percentage of positive signals for each IL-33 immunoassay. Shown are the discrepancies between the relative number of positive signals for the Quantikine, GenWay, EnzoLS, and DuoSet IL-33 immunoassays, by comparing the percentage of signals above background and above the lower limit of detection of each assay.

To evaluate specificity and sensitivity of the assays, we tested whether these were able to accurately quantify a known concentration of IL-33 when serum was present or in the presence of its soluble receptor IL-1RL1-a. This is important as IL-33 may exist in both free and IL-1RL1-a complexed forms in serum [1, 4]. Both serum and recombinant IL-1RL1-a interfered significantly with the quantification of IL-33 in two of these ELISA kits (Fig. 1c). The Quantikine kit showed accurate detection of recombinant IL-33 irrespective of serum dilution and the presence of IL-1RL1-a, indicating its technical feasibility of measuring IL-33 in serum, at least up to its LLD. These data strongly suggest that the high IL-33 measurements using the DuoSet kit in our asthma patients are unreliable, as the more sensitive and specific Quantikine kit did not measure IL-33 in any of these serum samples.

The overall lack of IL-33 detection in our serum samples suggests that IL-33 is present at very low levels in serum of these patients limiting our ability to study serum IL-33. Therefore, the activity of the IL-33/IL-1RL1 pathway might specifically be increased in severe asthma or during exacerbations, as suggested by studies correlating IL-33/IL-1RL1 levels with asthma severity [5–7], or it may indicate that serum is not the best compartment to study IL-33 levels, as IL-33 protein has previously been detected in BALF of patients with mild and moderate asthma severity [5].

Another explanation for the lack of detection of IL-33 in serum samples would be that the IL-33 present in serum has undergone post translational modifications that preclude its detection by the antibodies used in these kits, such as cleavage by cathepsins or elastase. Unfortunately, detailed information on the exact IL-33 epitope detected by the antibodies used in these ELISA kits is lacking to experimentally test this. As far as we are aware, no (proteomics) study has investigated the
exact protein isoforms of IL-33 present in human serum, which we think are useful to enable the development of methods to detect specific IL-33 isoforms and to improve the availability of such information.

Finally, the low levels of IL-33 detected in serum may be explained by the presence of interfering factors in serum such as IL-1RL1-a, as we find that both serum and recombinant IL-1RL1-a (sST2) interfere with accurate quantification of IL-33 in a dose-dependent manner in the GenWay and DuoSet ELISA kits. Hence, the level of IL-1RL1-a in serum should perhaps be treated as a covariate when using these kits. Nevertheless, as the maximum interfering effect of IL-1RL1-a is less than the effect of serum, at least in the DuoSet (see Fig. 1c), other factors may be present in serum that interfere with accurate detection of IL-33, such as serum globulins and albumins, potentially further complicating the use of these assays.

Other studies in allergic disorders have reported difficulties in detecting IL-33 in serum using ELISA, ranging from zero positive samples (n = 24 allergic rhinitis patients using the Quantikine kit [8]) to detectable values in every sample, but at the lower range of the standard curve (n = 37 wheezing children using the GenWay kit [6]). Furthermore, also in a non-allergic inflammatory disorder (Sjögren), measurement of IL-33 by the currently used immunoassays was shown to be problematic [9]. Digital or multiplex immunoassays could be promising novel methods in the measurement of IL-33 [10].

In summary, we show that 1) IL-33 is difficult to detect by ELISA in human serum, due to lack of sensitivity and specificity of currently available assays, 2) human serum interferes with IL-33 quantification in part through IL-1RL1-a, and 3) using non-serum certified kits may lead to spurious findings. We suggest that the data generated in the current study should be taken into account for prospective and retrospective studies of human serum IL-33 levels using these existing kits.

Acknowledgements

M. Ketelaar was supported by a joint ERS/EMBO Long-Term Research Fellowship 2013-2060, as part of her
MD-PhD programme. The Dutch Asthma Study (G. Koppe-
lman) was funded by the Netherlands Lung Founda-
tion, grants 95.09, 98.48, and 3.2.09.081JU. The 
Asthma UK Study (I. Sayers) was supported by Asthma 
UK Grant AUK-PG-2013-188. MEC approval numbers 
are MREC/99/4/001 and UK CRN 11820/IRAS 97142.

Author contributions
M. Ketelaar/M. Nawijn/G. Koppelman/I. Sayers designed 
the study. M. Ketelaar completed the experimental work 
and statistical analyses. D. Shaw and G. Koppelman col-
lected clinical samples and patient information. All 
authors contributed to the design, interpretation of data, 
and revision of the article. All authors had access to the 
data and read and approved the final manuscript.

Conflict of interests
The authors declare no conflict of interests.

References
1 Grotenboer NS, Ketelaar ME, Koppel-
man GH, Nawijn MC. Decoding 
asthma: translating genetic variation 
in IL33 and IL1RL1 into disease patho-
physiology. J Allergy Clin Immunol 
2013; 131:856–65.
2 Portelli MA, Hodge EF, Sayers I. 
Genetic risk factors for the develop-
ment of allergic disease identified by 
gene-wide association. Clin Exp 
Allergy 2015; 45:21–31.
3 Licona-Limon P, Kim IK, Palm NW, 
Flavell RA. TH2, allergy and group 2 
native lymphoid cells. Nat Immunol 
2013; 14:536–42.
4 Afonina IS, Muller C, Martin SJ, 
Beyaert R. Proteolytic processing of 
interleukin-1 family Cytokines: varia-
tions on a common theme. Immunity 
2015; 42:991–1004.
5 Prefontaine DF, Nadigel J, Chouiali F 
et al. Increased IL-33 expression by 
epithelial cells in bronchial asthma. J 
Allergy Clin Immunol 2010; 125:752– 
4.
6 Hamzaoui A, Berraies AF, Kaabachi 
WF, Haifa MF, Ammar JF, Kamel H. 
Induced sputum levels of IL-33 and 
soluble ST2 in young asthmatic chil-
dren. J Asthma 2013; 50:803–9.
7 Guo Z, Wu JF, Zhao JF et al. IL-33 
promotes airway remodeling and is a 
marker of asthma disease severity. J 
Asthma 2014; 51:863–9.
8 Asaka D, Yoshikawa MF, Nakayama 
TF, Yoshimura TF, Moriyama HF, 
Otori N. Elevated levels of inter-
leukin-33 in the nasal secretions of 
patients with allergic rhinitis. Int 
Arch Allergy Immunol 2012; 158 
(Suppl. 1):47–50.
9 Rivière E, Ly B, Boudaoud S et al. Pit-
falls for detecting interleukin-33 by 
ELISA in the serum of patients with 
primary Sjögren syndrome: compar-
ison of different kits. Ann Rheum Dis 
2016; 75(3):633–5
10 Voloshyna I, Mucci T, Sher J et al. 
Plasma IL-33 in atopic patients 
correlates with pro-inflammatory 
cytokines and changes cholesterol 
transport protein expression: a sur-
prising neutral overall impact on 
atherogenicity. Clin Exp Allergy 
2015; 45:1554–65.